New FDA-approved disease-modifying therapies for multiple sclerosis

Clinical Therapeutics

Volumn 37, Issue 4, 2015, Pages 691-715

  English, Clayton ^a,b   Aloi, Joseph J ^b  

^a Vermont Campus ^*  (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

cost disease modifying treatments multiple sclerosis new drugs pharmacotherapy

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; CROTONIC ACID DERIVATIVE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; PEGINTERFERON BETA1A; TERIFLUNOMIDE; TOLUIDINE DERIVATIVE;

DRUG APPROVAL; DRUG COST; ECONOMICS; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIPLE SCLEROSIS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ANTIBODIES, MONOCLONAL, HUMANIZED; CROTONATES; DIMETHYL FUMARATE; DRUG APPROVAL; DRUG COSTS; FINGOLIMOD HYDROCHLORIDE; GLATIRAMER ACETATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS; POLYETHYLENE GLYCOLS; TOLUIDINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84937763512     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.03.001     Document Type: Review

References (84)

1. L.P. Rowland, T.A. Pedley, and H.H. Merritt Merritt's Neurology. 12th ed 2010 Lippincott Williams & Wilkins Philadelphia, Pa
2. A. Compston, and A. Coles Multiple sclerosis Lancet 372 2008 1502 1517
3. G. Kobelt, J. Berg, D. Atherly, and O. Hadjimichael Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States Neurology 66 2006 1696 1702
4. A.S. Mathis Managed care aspects of managing multiple sclerosis Am J Manag Care 19 2 suppl 2013 S28 S34
5. H.L. Zwibel, and J. Smrtka Improving quality of life in multiple sclerosis: an unmet need Am J Manag Care 17 suppl 5 2011 S139 S145
6. Aubagio (teriflunomide) [package insert]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/202992s001lbl.pdf. Accessed December 18, 2014.
7. Betaseron (inteferon beta-1b) [package insert]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/103471s5185lbl.pdf. Accessed December 20, 2014.
8. Extavia (inteferon beta-1b) [package insert]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/125290s0000lbl.pdf. Accessed December 20, 2014.
9. Avonex (interferon beta-1a) [package insert]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/103628s5129s5177s5194s5224lbl.pdf. Accessed December 20, 2014.
10. Rebif (interferon beta-1a) [package insert]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/103780s5178s5179lbl.pdf. Accessed December 27,2014.
11. Copaxone (glatiramer acetate) [package insert]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/020622s089lbl.pdf. Accessed December 30, 2014.
12. Gilenya (fingolimod) [package insert]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022527s009lbl.pdf. Accessed December 27, 2014.
13. Novantrone (mitoxantrone) [package insert]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/019297s035lbl.pdf. Accessed December 20, 2014.
14. Tysabri (natalizumab) [package insert]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125104s840s847s889lbl.pdf. Accessed December 27, 2014.
15. Tecfidera (dimethyl fumarate) [package insert]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204063s003s008s010lbl.pdf. Accessed December 18, 2014.
16. Plegridy (peginterferon beta-1a) [package insert]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125499lbl.pdf. Accessed December 15, 2014.
17. Lemtrada (alemtuzumab) [package insert]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/103948s5139lbl.pdf. Accessed December 26, 2014.
18. Red Book Online. Ann Arbor, Mich; Truven Healthy Analytics. http://www.micromedexsolutions.com/micromedex2/librarian/ND-T/evidencexpert/ND-PR/evidencexpert/CS/C576EE/ND-AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/FB3F34/ND-PG/evidencexpert/ND-B/evidencexpert/ND-P/evidencexpert/PFActionId/redbook.FindRedBook?navitem=topRedBook. Accessed December 29, 2014.
19. J. Chun, and H.P. Hartung Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis Clin Neuropharmacol 33 2010 91 101
20. L. Kappos, E.W. Radue, and P. O'Connor A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 2010 387 401
21. J.A. Cohen, F. Barkhof, and G. Comi Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 2010 402 415
22. M. Agius, X. Meng, and P. Chin Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom CNS Neurosci Ther 20 2014 446 451
23. P.A. Calabresi, E.W. Radue, and D. Goodin Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial Lancet Neurol 13 2014 545 556
24. L. Kappos, J. Antel, and G. Comi Oral fingolimod (FTY720) for relapsing multiple sclerosis N Engl J Med 355 2006 1124 1140
25. P. O'Connor, G. Comi, and X. Montalban Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study Neurology 72 2009 73 79
26. G. Comi, P. O'Connor, and X. Montalban Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results Mult Scler 16 2010 197 207
27. B. Khatri, F. Barkhof, and G. Comi Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study Lancet Neurol 10 2011 520 529
28. FDA Drug Safety Communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod). http://www.fda.gov/drugs/drugsafety/ucm366529.htm. Accessed December 30, 2014.
29. A. Bar-Or, A. Pachner, and F. Menguy-Vacheron Teriflunomide and its mechanism of action in multiple sclerosis Drugs 74 2014 659 674
30. P. O'Connor, J.S. Wolinsky, and C. Confavreux Randomized trial of oral teriflunomide for relapsing multiple sclerosis N Engl J Med 365 2011 1293 1303
31. P.W. O'Connor, D. Li, and M.S. Freedman A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses Neurology 66 2006 894 900
32. M.S. Freedman, J.S. Wolinsky, and B. Wamil Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial Neurology 78 2012 1877 1885
33. Center for Drug Evaluation and Research. Application Number 202992Orig1s000 Medical Reviews. 2012. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2012/202992Orig1s000MedR.pdf. Accessed December 29, 2014.
34. A. Bar-Or, M.S. Freedman, and M. Kremenchutzky Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis Neurology 81 2013 552 558
35. C. Confavreux, P. O'Connor, and G. Comi Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Neurol 13 2014 247 256
36. A.E. Miller, J.S. Wolinsky, and L. Kappos Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Neurol 13 2014 977 986
37. P. Vermersch, A. Czlonkowska, and L.M. Grimaldi Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial Mult Scler 20 2014 705 716
38. C. Confavreux, D.K. Li, and M.S. Freedman Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years Mult Scler 18 2012 1278 1289
39. P.W. O'Connor, F.D. Lublin, and J.S. Wolinsky Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use J Neurol 260 2013 2472 2480
40. A.E. Miller, R. Macdonell, and G. Comi Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study J Neurol 261 2014 1781 1788
41. Leist T, Freedman M, Benamor M, et al. [P2.203] Pooled safety data from four placebo-controlled teriflunomide studies. Paper presented at: American Academy of Neurology 2014 Annual Meeting; April 29, 2014; Philadelphia, Pa.
42. R.J. Fox, D.H. Miller, and J.T. Phillips Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N Engl J Med 367 2012 1087 1097
43. R. Gold, L. Kappos, and D.L. Arnold Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N Engl J Med 367 2012 1098 1107
44. L. Kappos, R. Gold, and D.H. Miller Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study Lancet 372 2008 1463 1472
45. L. Kappos, R. Gold, and D.L. Arnold Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study Mult Scler 20 2014 243 252
46. M. Kita, R.J. Fox, and J.T. Phillips Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study Mult Scler 20 2014 253 257
47. A. Bar-Or, R. Gold, and L. Kappos Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study J Neurol 260 2013 2297 2305
48. M. Hutchinson, R.J. Fox, and D.H. Miller Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study J Neurol 260 2013 2286 2296
49. FDA Drug Safety Communication: FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate). http://www.fda.gov/Drugs/DrugSafety/ucm424625.htm. Accessed December 10, 2014.
50. van Oosten BW, Killestein J, Barkhof F, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy [published correction apears in N Engl J Med. 2013;368:1950]. N Engl J Med. 2013;368:1658-1659.
51. Long-Term Safety and Efficacy Extension Study of Oral BG00012 Monotherapy in Relapsing-Remitting Multiple Sclerosis. Clinical Trial NCT00835770. https://www.clinicaltrials.gov/ct2/show/NCT00835770?term=dimethyl+fumarate&rank=16. Accessed December 20, 2014.
52. P.H. Lalive, O. Neuhaus, and M. Benkhoucha Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action CNS Drugs 25 2011 401 414
53. V.W. Yong Differential mechanisms of action of interferon-beta and glatiramer acetate in MS Neurology 59 2002 802 808
54. J.A. Cohen, M. Rovaris, and A.D. Goodman Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS Neurology 68 2007 939 944
55. G. Comi, J.A. Cohen, D.L. Arnold FORTE Study Group Phase III dose-comparison study of glatiramer acetate for multiple sclerosis Ann Neurol 69 2011 75 82
56. S. Messina, and F. Patti The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment Expert Opin Drug Metab Toxicol 9 2013 1349 1359
57. O. Khan, P. Rieckmann, A. Boyko GALA Study Group Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis Ann Neurol 73 2013 705 713
58. R. Reuss PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update Biologics 7 2013 131 138
59. L. Durelli, E. Verdun, and P. Barbero Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) Lancet 359 2002 1453 1460
60. H. Panitch, D.S. Goodin, and G. Francis Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial Neurology 59 2002 1496 1506
61. E. Portaccio, and M.P. Amato Improving compliance with interferon-beta therapy in patients with multiple sclerosis CNS Drugs. 23 2009 453 462
62. X. Hu, L. Miller, and S. Richman A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology J Clin Pharmacol 52 2012 798 808
63. Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers. Clinical Trial NCT 02269930. http://www.clinicaltrials.gov/ct2/show/NCT02269930?term=BIIB017&rank=4. Accessed December, 20 2014.
64. P.A. Calabresi, B.C. Kieseier, and D.L. Arnold Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study Lancet Neurol 13 2014 657 665
65. B.C. Kieseier, D.L. Arnold, and L.J. Balcer Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE Mult Scler 2014 Nov 28 [Epub ahead of print]
66. Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN). Clinical Trial NCT 01332019. http://www.clinicaltrials.gov/ct2/show/NCT01332019?term=01332019&rank=1. Accessed December 26, 2014.
67. CAMMS223 Trial Investigators A.J. Coles, and D.A. Compston Alemtuzumab vs. interferon beta-1a in early multiple sclerosis N Engl J Med 359 2008 1786 1801
68. J.A. Cohen, A.J. Coles, and D.L. Arnold Alemtuzumab versus interferon beta-1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial Lancet 380 2012 1819 1828
69. A.J. Coles, C.L. Twyman, and D.L. Arnold Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial Lancet 380 2012 1829 1839
70. A.J. Coles, E. Fox, and A. Vladic Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial Neurology 78 2012 1069 1078
71. IMS Institute for Healthcare Information. Medicine use and shifting costs of healthcare: a review of the use of medicines in the United States in 2013. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Secure/IIHI-US-Use-of-Meds-for-2013.pdf. Accessed December 20, 2014
72. A.M. Lotvin, W.H. Shrank, and S.C. Singh Specialty medications: traditional and novel tools can address rising spending on these costly drugs Health Aff (Millwwod) 33 2014 1736 1744
73. N. Agashivala, H. Dastani, R. Carlton, and E. Sarnes Cost-effectiveness of fingolimod in treating patients with relapsing-remitting multiple sclerosis Am J Pharm Benefits 3 2011 320 328
74. N. Agashivala, and E. Kim Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis Clin Ther 34 2012 1583 1590
75. S. Lee, D.C. Baxter, and B. Limone Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States J Med Econ 15 2012 1088 1096
76. K. O'Day, K. Meyer, and R.M. Miller Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis J Med Econ 14 2011 617 627
77. X. Zhang, J.W. Hay, and X. Niu Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-beta1a in relapsing-remitting multiple sclerosis CNS Drugs 29 2015 71 81
78. D. Yamamoto, and J.D. Campbell Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature Autoimmune Dis 2012 2012 784364
79. J. Sharac, P. McCrone, and R. Sabes-Figuera Pharmacoeconomic considerations in the treatment of multiple sclerosis Drugs 70 2010 1677 1691
80. Red Book Pharmacy's Fundamental Reference 114 ed 2010 Thomson Reuters (Healthcare) Inc Montvale, N J
81. National Institute for Health and Care Excellence. Multiple sclerosis: management of multiple sclerosis in primary and secondary care. http://www.nice.org.uk/Guidance/CG186. Accessed December 30, 2014.
82. M. Perry, S. Swain, S. Kemmis-Betty, and P. Cooper Guideline Development Group of the National Institute for Health and Care Excellence. Multiple sclerosis: summary of NICE guidance BMJ 349 2014 g5701
83. P.S. Sorensen New management algorithms in multiple sclerosis Curr Opin Neurol 27 2014 246 259
84. V. Limmroth Treatment of relapsing-remitting multiple sclerosis: current and future algorithms Eur Neurol 72 Suppl 1 2014 35 38